GLP-1 Agonist Therapy Center

Glucagon-like peptide 1 (GLP-1) slows the accelerated gastric emptying associated with hypoglycemia, according to a crossover study….

Possibility of non-subcutaneous administration could increase patient compliance….  GLP-1 agonists are effective therapeutic options for treating diabetes. While their effectiveness has been established, compliance with these medications may be limited in some patients due to their subcutaneous route of administration and gastrointestinal adverse effects. In a recent prospective, double-blind, placebo-controlled …

A study shows GLP-1 agonists slow the acceleration of gastric emptying that occurs as a result of insulin-induced hypoglycemia…. Glucagon-like peptide 1 (GLP-1) receptor agonists are used as monotherapy, secondary therapy with other oral agents, and in combination with basal insulin for management of type 2 diabetes. Though they are …

Although glucagon-like peptide-1 (GLP-1) is highly biologically active following intravenous or subcutaneous injection, a non-injectable alternative for activating GLP-1 receptor signaling would clearly be desirable. Studies by Gutniak, Ahren and colleagues in Sweden have shown that GLP-1 formulated in buccal tablets is absorbed into the circulation and lowers blood glucose …

David Joffe, BSPharm, CDE  Brittany Davis, Pharm D Candidate, Presbyterian College School of Pharmacy The molecular mechanisms linking fatty acids to GLP-1 secretion from gut endocrine cells remain incompletely understood. Hirasawa and colleagues have identified a GPCR, designated GPR120 that serves as a receptor for fatty acids on gut endocrine cells. …

David Joffe, BSPharm, CDE Brittany Davis, Pharm D Candidate, Presbyterian College School of Pharmacy This is the first of a two-part series that examines some of the current research and unanswered questions about how GLP-1 is made in the body, what factors are involved in the release and quantity of …

Prior reports of GLP-1 vasoprotective effects may not be valid…. Prior reports have shown that GLP-1 concentrations are associated with anti-inflammatory and atheroprotective effects which extend to cardioprotection during acute myocardial infarction. In the body, GLP-1 binds to its receptors on pancreatic beta-cells leading to glucose dependent insulin release. Studies …

How to unlock GLP-1 drugs’ full glucose-lowering potential…. The current subcutaneous delivery method of GLP-1 agonist drugs for patients with type 2 diabetes may not be the most effective. According to Michael Nauchk, MD, intravenously administered infusions of GLP-1 resulted in normalization of blood glucose without gastrointestinal upset, while subcutaneous …

Dr. Cyrus Desouza, MBBS, talks about the cardiovascular side effects of newer classes of drugs. SGLT2 inhibitors are still relatively new so there is not much information but they do show some weight loss effects, seem to lower blood pressure, and may have some CV benefits. However, we don’t know what they …

Dr. Cyrus Desouza, MBBS, talks about the GLP-1s, of which several are already in the market with more in the pipeline. He believes that his is really an exciting class of drugs, particularly because of the weight loss effect, which is a big deal for patients. In addition, there may be …